The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical utility and cost-effectiveness of a molecular biomarker for immune checkpoint inhibitor response monitoring and treatment decisions.
 
Zachary Rivers
Employment - Tempus AI, Inc
Stock and Other Ownership Interests - Tempus AI
Research Funding - Bayer; Tempus AI
Travel, Accommodations, Expenses - Tempus AI
 
Akash Mitra
Employment - Guardant Health; Tempus
Stock and Other Ownership Interests - Guardant Health; Tempus
 
Victoria Chiou
Employment - AstraZeneca; Tempus AI, Inc.
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca; Tempus AI, Inc.
Travel, Accommodations, Expenses - AstraZeneca; Tempus AI, Inc.
 
Halla Nimeiri
Employment - Northwestern Medicine; Tempus AI
Stock and Other Ownership Interests - Abbvie; Tempus AI
 
Sheetal Kircher
Stock and Other Ownership Interests - Abbott/AbbVie
 
David Stenehjem
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Aprea Therapeutics; Bristol-Myers Squibb; Dracen; In Silico; Indaptus; Iterion Therapeutics; Mirati Therapeutics; Molecular Templates; Salarius Pharmaceuticals; Schrodinger; SonaCare Medical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bioverativ (Inst); Bristol-Myers Squibb (Inst); Jazz Pharmaceuticals (Inst); Novartis (Inst)
 
Rotem Ben-Shachar
Employment - Myriad Genetics; Tempus AI
Stock and Other Ownership Interests - Myriad Genetics; Tempus
 
Charu Aggarwal
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novocure; Pfizer; Sanofi/Regeneron; Takeda
Speakers' Bureau - AstraZeneca (I)
Research Funding - AstraZeneca/MedImmune (Inst); Candel Therapeutics (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Loxo@Lilly (Inst); Merck Sharp & Dohme (Inst)